Anebulo Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Tables)

9 Months Ended

Mar. 31, 2021

The following table provides the assumptions used in determining the fair value of option awards as of March 31, 2021:

Changes in awards granted under the 2020 Stock Plan as of March 31, 2021 are as follows:

	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value

Outstanding at December 31, 2020		982,500	$	0.1083		0.96	$	2,038,688
Granted		604,404	$	2.1833
Exercised		-	$	-
Forfeited		-	$	-
Outstanding at March 31, 2021		1,586,904	$	0.8986		2.6	$	2,038,688
Options exercisable at March 31, 2021		383,418	$	0.1895		1.7	$	764,467